心血管内科患者药物不良反应因素筛选及Logistic分析

摘要/Abstract

摘要： 目的：系统分析研究心血管内科住院患者药品不良反应（ADR）发生的相关因素。方法：将2014~2016年收集的276例ADR病例按照累及的系统和涉及的药物种类进行分类分析，同时将2014~2016年入科的2 538例病例按照单因素分析，有意义的因素再纳入多因素Logistic回归分析。结果：ADR累及系统分类中以涉及心血管系统的损害居多，而涉及的药物主要以降压类药物以及抗血小板抗凝类药物为主。经多因素Logistic回归分析，年龄>65岁，住院时间>14d，使用药物>8种，诊断>4个，使用抗血小板及抗凝类药物具有明显的临床意义。结论：对于普遍使用的降压类药物以及抗血小板及抗凝类药物的患者，如果又伴发其他高危因素应采取预防措施降低ADR的发生率。

Abstract: Objective： To investigate the factors related to adverse drug reaction（ADR） with inpatient residents in cardiovascular department. Methods： 276 ADR reports during 2014~2016 were classified by the inflicted systems and the types of related drugs. 2 538 objectives who hospitalized in cardiovascular department during 2014~2016 were analyzed with single factor analysis. Then factors with statistical significance was analyzed with multivariate logistic analysis. Results： In ADR related system， the damage of cardiovascular systems was much higher， and for the related drug class， antihypertensive， antiplatelet and anticoagulant drugs were the mostly concerned. The significant factors included age more than 65， length of stay more than 14d， the kinds of drugs more than 8， diagnosis more than 4， antiplatelet and anticoagulant drugs use. Conclusion： To the patients using antihypertensive， antiplatelet and anticoagulant drugs with other high risks， it is necessary to take measures to reduce the rate of ADR.

张吕钊. 心血管内科患者药物不良反应因素筛选及Logistic分析[J]. .

zhanglvzhao. The Screen and Logistic Analysis on Factors of Adverse Drug Reactions among Patients in Cardiovascular Department[J]. .

参考文献

[1] 陈新谦，金有豫，汤光．新编药物学［M］． 16 版．北京: 人民卫生出版社， 2007．
[2]Trivalle C, Cartier T, Verny C, et al. Identifying and preventing adverse drug events in elderly hospitalized patients: a randomized trial of a program to reduce adverse drug events[J]. J Nutr Health Aging. 2010, 14(1):57-61.
[3]Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score[J]. Archives of internal medicine.2010, 17(13):1142-1148.
[4]O’Connor MN, Gallagher P, Byrne S, et al. Adverse drug reactions in older patients during hospitalization: are they predictable? [J]. Age aging, 2013 ,190(2):623.
[5] Tangiisuran B, Scutt G, Stevenson J, et al. Development and validation of a risk model for predicting adverse drug reactions in older people during hospital stay: Brighton Adverse Drug Reactions Risk (BADRI) model[J]. PLoS One.2014 30;9(10):e111254.
[6]Onder G, Gambassi G, Scales CJ, et al. Adverse drug reactions and cognitive function among hospitalized older adults[J]. Eur J Clin Pharmacol, 2000,58 (5):371-377.
[7]Fattinger K, Roos M, Vergeres P, et al. Epidemiology of drug exposre and adverse drug reations in two swiss department s of internal medicine[J]. Br J Clin Pharmacol. 2000,49 (2):158-167.
[8]Corsonello A, Pedone C, Corica F, et al.Concelaed renal failure and adverse drug reactions in older patients with type 2 diabetes mellitus[J]. J Gerontol A Biol Sci Med Sci.2005,60 (9):1147-1151.
[9]Howard RI, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review[J]. Br J Clin Pharmacol. 2007,63 (2):136-147.
[10] Pichler WJ, Adam J, Daubner B, Gentinetta T, Keller M, Yerly D. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin N Am 2010;94:645–64
[11]Chaudhry T, Hissaria P, Weise M, Heddle B, Kette F, Smith WB. Oral drug challenges in non-steroidal anti-inflammatory drug-induced urticaria, angioedema and anaphylaxis. Intern Med J 2012;42:665–71.
[12] Palaian S., Ibrahim M. I., Mishra P. Health professionals' knowledge, attitude and practices towards pharmacovigilance in Nepal. Pharmacy Practice. 2011;9(4):228–235
[13]Gupta S. K., Nayak R. P., Shivaranjani R., Vidyarthi S. K. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. Perspectives in Clinical Research. 2015;6(1):45–52.
[14] Ishiguro C., Hall M., Neyarapally G. A., Dal Pan G. Post-market drug safety evidence sources: an analysis of FDA drug safety communications. Pharmacoepidemiology and Drug Safety.2012;21(10):1134–1136.
[15] Abubakar A. R., Simbak N. B., Haque M. A systematic review of knowledge, attitude and practice on adverse drug reactions and pharmacovigilance among doctors. Journal of Applied Pharmaceutical Science. 2014;4(10):117–127.
[16] Kamal N. N., Kamel E. G., Mahfouz E. M. Adverse drug reactions reporting, knowledge, attitude and practice of physicians towards it in El Minia University Hospitals. International Public Health Forum.2014;1(4):13–17.
[17]Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008; 42: 1017–1025.
[18]Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011; 15: 1–204.
[19] D'Incau P, Lapeyre-Mestre M, Carvajal A, Donati M, Salado I, Rodriguez L, et al. No differences between men and women in adverse drug reactions related to psychotropic drugs: a survey from France, Italy and Spain. Fundam Clin Pharmacol. 2014; 28: 342–348.
[20] Lee S, Kim HY, Lee KH, Koo HK, Kim Y. Analysis of Hospital Admissions Related to Adverse Drug Events Using ADE Signals. J Appl Pharmacol. 2006; 14: 56–65.

快速检索引用检索图表检索高级检索